Der Forschungsverbund HiChol ist Teil der „translationsorientierten Verbundvorhaben im Bereich der Seltenen Erkrankungen“, gefördert durch das Bundesministerium für Bildung und Forschung im Rahmen von Research 4 Rare. Es werden deutschlandweite Expertisen zusammengeführt, die durch eine problemlösungsorientierte und interdisziplinäre Zusammenarbeit neue Erkenntnisse zu Seltenen Erkrankungen erarbeiten. Die Erforschung Seltener Erkrankungen verspricht auch modellhafte Erkenntnisse, die auf andere häufigere Erkrankungen übertragen werden können. Weitere Informationen unter https://www.research4rare.de/.

2024 marks the 7th year of the Disruptive Technology Award Competition. ADLM’s Disruptive Technology Award Competition (DTAC) aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care. Apply for the chance to present your cutting-edge technology at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) – the premier international forum for unveiling groundbreaking advances in laboratory medicine. About ADLM 2024 ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) has a rich 75-year history as the premier destination to discover the latest innovations in laboratory medicine and meet the ever-evolving needs of the laboratory medicine profession.  This year’s conference is July 28 – August 1, in Chicago, IL, USA.  At ADLM 2024, immerse yourself in thought-provoking discussions, learn about the latest ground-breaking research, discover a wide array of… 

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval. P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumors. JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation. Studies shows that, JAB-30300 has shown very high binding affinity to P53 Y220C mutant proteins. Tumor regression was achieved in multiple cancer models covering various…